Medical insurance payment standard pilot, some drugs abnormal price increase was reported!

[industry trends of pharmaceutical network] recently, the health and Health Commission of Inner Mongolia Autonomous Region issued the notice on abnormal price increase behavior of some drugs in the pilot payment standard of basic medical insurance drugs in Inner Mongolia Autonomous Region in 2019 (hereinafter referred to as the notice) According to the notice, on May 17, 2019, the Medical Security Bureau of the autonomous region issued the notice on the pilot work of drug payment standards for basic medical insurance in Inner Mongolia Autonomous Region, and selected cefazolin, sodium chloride and glucose as three drugs to carry out the pilot work Because the original purchase price of some pilot drugs is relatively low, after the publication of the pilot standards, there has been a phenomenon that the purchase price has been greatly increased or even directly increased to the medical insurance payment standard, increasing the burden of patients' drug costs and medical insurance fund expenditures For example, for glucose injection, some pharmaceutical companies increased the price of (250ml: 12.5g) specification from 1.6 yuan to 3.08 yuan, which was the same as the payment standard of medical insurance, with an increase of 92.5%, and (500ml: 25g) specification from 1.9 yuan to 3.51 yuan, with an increase of 84.74% In addition, for the sodium chloride injection (500ml: 4.5g), some pharmaceutical companies increased the bargaining price from 2.13 to 3.51 yuan, or 64.79% At the same time, 9 hospitals are also in the scope of notification In response to the above-mentioned acts of disrupting drug purchase and raising prices abnormally, the Medical Security Bureau of the autonomous region severely criticized them, and made relevant decisions on the treatment of related drugs, enterprises and purchasing medical institutions Among them, for the drugs involved, it is required to suspend the qualification of online purchase of drugs that significantly increase the purchase price and directly raise the purchase price to the medical insurance payment standard from August 6, 2019 For the involved enterprises, the relevant enterprises are required to submit the reasons for the abnormal price increase, supporting materials and rectification to the centralized procurement service center of pharmaceutical machinery of the autonomous region before August 9, 2019 If the relevant pharmaceutical companies maliciously raise the price, or fail to explain the reasons on time and report the rectification situation, or the reasons for raising the price are insufficient and refuse to rectify, they will be included in the blacklist of pharmaceutical machinery procurement in the autonomous region, and the qualification of online procurement of relevant pharmaceuticals in the region will be suspended from August 12, 2019 In addition, the medical institutions and distribution enterprises involved will be interviewed and ordered to make rectification within a time limit, and the interview and rectification will be submitted to the Medical Security Bureau of the autonomous region before August 9, 2019 If a medical institution fails to implement or the designated medical service agreement is terminated, the drug distribution enterprise or the drug distribution enterprise is listed in the blacklist of the distribution enterprise, and the enterprise's distribution qualification in the region to which it belongs is lost The essence of basic medical insurance drug payment standard pilot work is to further implement the requirements of national basic medical insurance system reform, and promote the establishment of incentive and risk sharing mechanism of "surplus retention, reasonable overspending sharing" between medical insurance agencies and medical institutions In short, the purpose is to guide the formation of a reasonable price through the adjustment of medical insurance payment standards, so that medical institutions and patients can form a reasonable drug habit This is also conducive to reducing the burden of drug use of patients, so that the people can use drugs However, the behavior of maliciously raising the price of relevant pharmaceutical companies or medical institutions is not conducive to the pilot work, and will also bring pressure to patients' drug costs This time, 5 enterprises and 11 medical institutions were notified, and the qualification of medical insurance designated point was cancelled While warning these pharmaceutical companies and medical institutions, it is believed that it will also alert other enterprises that intend to substantially increase the price of pilot drugs and drill holes.